Research and Clinical Trials

A Phase III randomized, placebo controlled, double-blind trial of sorafenib plus erlotinib vs. sorafenib plus placebo as first line systemic treatment for hepatocellular carcinoma (HCC – liver cancer)
Brief Description  
This is a randomized study to evaluate the clinical benefit of sorafenib 400 mg twice daily and erlotinib 150 mg once a day versus sorafenib 400 mg twice daily and placebo erlotinib once daily in subjects with unresectable advanced or metastatic Child-Pugh A hepatocellular carcinoma (HCC - liver cancer). Patients who are candidates for potentially curative intervention (i.e. surgical resection or transplant ) are not eligible for this study.
Who may be Eligible  
Male or Female patients at least 18 years of age with unresectable Hepatocellular Carcinoma
Liver cancer
IRB Number  
Principal Investigator  
Russo, Mark

For More Information, Contact  Gale  W, Groseclose
Phone:  (704) 355-4875  Fax:  (704) 355-8147  
Address:Carolinas Medical Center 1000 Blythe Boulevard Charlotte, NC 28232